Project Grant R01EY035215
Award Date
9/30/24
Completion Date
8/31/27
Dollars Obligated
$589K
Funding Federal Agency
Office of the Director
Awarding Federal Agency
National Eye Institute
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
This Project Grant award by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $583,250 to The Schepens Eye Research Institute, Inc. to identify the mechanisms underlying ocular toxicity caused by nitrogen mustard exposure and evaluate specialized lipid mediators as potential medical countermeasures.
The key objectives are to: 1) Determine how nitrogen mustard alters the function of conjunctival goblet cells and...
This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $961,980 to the University of Illinois to investigate the role of cellular senescence in the development of Mustard Gas Keratopathy (MGK), a severe and delayed form of corneal disease that can occur after exposure to chemical warfare agents.
The key objectives are to: 1) Examine the impact of senescence and associated inflammatory signaling (SASP) on the progression...
The federal Project Grant award, with ID R56EY036320, was provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The $937,468 award, granted to Northwestern University, supports research to understand the pathological mechanisms of sulfur mustard gas keratopathy (MGK) in the cornea. The key objectives are to: (1) explore whether nitrogen mustard (an analog of sulfur mustard) exposure affects the binding of the autophagy-regulator...
This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support (CFDA 93.310) program provides $498,248 to the University of Connecticut Health Center (UCHC) to investigate the molecular mechanisms underlying corneal and retinal injury caused by exposure to chemical threat agents like nitrogen mustard. The key objectives are to: 1) Examine the role of the p53-PAD axis in driving corneal hypercitrullination, a pathological response, after nitrogen...
This Project Grant award from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) will provide $482,242 to The Medical College of Wisconsin, Inc. to conduct research on the mechanisms of mustard gas toxicity in the retina using a minipig model. The project aims to characterize the in vivo clinical, structural, and functional changes in the retina of a minipig model exposed to mustard gas, and identify molecular targets involved in retinal degenerative...
This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $208,073 to the University of Connecticut Health Center (UCHC) to conduct research on targeting corneal Schwann cells to counteract toxin injury. The research aims to identify novel druggable targets and biomarkers in corneal Schwann cells and to evaluate FDA-approved drugs for their potential to support axonal regeneration following acute and chronic stages of...
This Project Grant award, with ID R21EY035974, is funded by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The award totaling $223,495 is provided to Virginia Commonwealth University (VCU) to evaluate a novel approach for effective treatment of nitrogen mustard (NM)-induced corneal injury in rat and rabbit models.
The research aims to develop biodegradable nanoparticles of dexamethasone sodium phosphate (DSP) with poly(lactic-co-glycolic...
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,477,500 Project Grant to The Schepens Eye Research Institute, Inc., a non-profit organization affiliated with Harvard Medical School and Massachusetts Eye and Ear. The 3-year grant, awarded on September 1, 2023, will fund research on "Topical Calcitonin Gene-Related Peptide for Corneal Injury Prevention and Regeneration." The Schepens Eye Research Institute, which has...
The Schepens Eye Research Institute, Inc. was awarded a $1,475,676 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 1, 2022 to August 31, 2025 to develop concomitant topical treatments for pain and inflammation resulting from ocular injuries. The Military Medical Research and Development program supports biomedical research that transforms military and public...
The Defense Health Agency awarded a $498,896 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to The Schepens Eye Research Institute, Inc. in Boston, MA. The grant supports a 2-year research project investigating the use of noninvasive transpalpebral electrical stimulation as a therapy for combat-related corneal trauma. As an experienced performer of prior federal grants from agencies like the NIH, DoD, and Army, the non-profit Schepens Eye Research...